Sara A. Hurvitz, MD, on Potentially Practice-Changing Findings on T-DXd vs T-DM1 in Metastatic Breast Cancer

Posted: Thursday, December 8, 2022

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical implications of new survival data from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. In addition, patients treated with T-DXd had a 36% lower risk of death than those treated with T-DM1.